Compare NAUT & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAUT | CYRX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.5M | 419.3M |
| IPO Year | 2020 | 2008 |
| Metric | NAUT | CYRX |
|---|---|---|
| Price | $2.39 | $15.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $4.00 | ★ $13.31 |
| AVG Volume (30 Days) | 424.8K | ★ 789.8K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.07 | ★ 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | $992.86 | $8.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.62 | $6.33 |
| 52 Week High | $4.31 | $16.73 |
| Indicator | NAUT | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 67.65 |
| Support Level | $2.22 | $7.98 |
| Resistance Level | $2.54 | N/A |
| Average True Range (ATR) | 0.19 | 0.66 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 15.00 | 70.73 |
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.